Logo

Quark Delayed Graft Function Drug Safe in Phase I

May 06, 2010
Premium

Quark Pharmaceuticals this week announced the release of phase I data showing its delayed graft function prophylaxis QPI-1002 to be safe in kidney transplant recipients.

QPI-1002, which is designed to silence p53, was tested in 40 transplant recipients of kidneys from deceased donors. Safety data show no dose-limiting toxicities in any cohort, Quark said, supporting the drug's continued development.

The full data from the study are currently under analysis, the company added.

Filed under

Gene Editing, Gene Silencing, & CRISPR
Disease Research
RNAi
siRNA
Quark
delayed graft function
Breaking News
The Scan

Self-Reported Hearing Loss in Older Adults Begins Very Early in Life, Study Says

A JAMA Otolaryngology — Head & Neck Surgery study says polygenic risk scores associated with hearing loss in older adults is also associated with hearing decline in younger groups.

Genome-Wide Analysis Sheds Light on Genetics of ADHD

A genome-wide association study meta-analysis of attention-deficit hyperactivity disorder appearing in Nature Genetics links 76 genes to risk of having the disorder.

MicroRNA Cotargeting Linked to Lupus

A mouse-based study appearing in BMC Biology implicates two microRNAs with overlapping target sites in lupus.

Enzyme Involved in Lipid Metabolism Linked to Mutational Signatures

In Nature Genetics, a Wellcome Sanger Institute-led team found that APOBEC1 may contribute to the development of the SBS2 and SBS13 mutational signatures in the small intestine.